Cardiol Therapeutics Inc. (CRDL)

Biological Products, (No Diagnostic Substances) · market cap $186M · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-12 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Cardiol Therapeutics Inc. (CRDL) is a small-cap Canadian biotech (18 employees, ~$122M market cap) focused exclusively on its lead asset CardiolRx, a cannabidiol-based anti-inflammatory/anti-fibrotic formulation in Phase 3 development for Acute Myocarditis. The company's entire near-term value proposition hinges on a single Phase 3 readout estimated around September 21, 2026, rated a 9/10 importance catalyst by CatalystAlert.

The catalyst path

2026-11-12 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
CardiolRx	Phase 3	Acute Myocarditis

Price & technical context

3-month

+48.6%

6-month

+11.4%

12-month

+45.8%

52-wk range

$0.93–$2.29

vs 50-day MA

-10.1%

vs 200-day MA

+21.6%

Realized vol

61.3%

Max drawdown

-67.3%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CRDL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.